v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Restructuring Reserve [Roll Forward]    
Balance, beginning [1] $ 1,910  
Provision [2] 49 $ 621
Utilization and other [3] (371)  
Balance, ending [4] 1,588  
Other Current Liabilities [Member]    
Restructuring Reserve [Roll Forward]    
Balance, beginning 1,400  
Balance, ending 1,200  
Other Noncurrent Liabilities [Member]    
Restructuring Reserve [Roll Forward]    
Balance, beginning 466  
Balance, ending 431  
Employee Termination Costs [Member]    
Restructuring Reserve [Roll Forward]    
Balance, beginning [1] 1,783  
Provision 15  
Utilization and other [3] (330)  
Balance, ending [4] 1,467  
Asset Impairment Charges [Member]    
Restructuring Reserve [Roll Forward]    
Balance, beginning [1] 0  
Provision 28  
Utilization and other [3] (28)  
Balance, ending [4] 0  
Exit Costs [Member]    
Restructuring Reserve [Roll Forward]    
Balance, beginning [1] 127  
Provision 6  
Utilization and other [3] (12)  
Balance, ending [4] $ 121  
[1] Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($466 million).
[2] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).
[3] Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
[4] Included in Other current liabilities ($1.2 billion) and Other noncurrent liabilities ($431 million).